07:00 , Jun 8, 2015 |  BC Week In Review  |  Company News

Alseres, Navidea deal

The partners terminated a 2012 deal granting Navidea exclusive, worldwide rights to develop and commercialize Altropane ( NAV5001 ). Navidea will be eligible to receive a milestone payment upon FDA approval plus royalties. Navidea said...
07:00 , Jul 14, 2014 |  BioCentury  |  Finance

2Q Stock Wrap-Up: Large and in charge

In contrast to the first quarter in which all market cap segments gained ground, only the large caps finished 2Q14 in the black. Gainers outnumbered decliners 20-12 in the over $5 billion segment, which was...
07:00 , Jun 2, 2014 |  BC Week In Review  |  Company News

Navidea diagnostic news

Navidea said it will decrease investment in two clinical imaging agents to reduce cash burn rate while it focuses resources on ramping up sales for imaging agent Lymphoseek tilmanocept. The company will seek partners for...
08:00 , Dec 9, 2013 |  BC Week In Review  |  Clinical News

Altropane: Phase III started

Navidea began an open-label, international Phase III trial to evaluate a single IV dose of NAV5001 in 275 patients with Parkinsonian syndromes. The company has an SPA from FDA for the trial and for a...
07:00 , Sep 2, 2013 |  BC Week In Review  |  Clinical News

Altropane: SPA received

Navidea Biopharmaceuticals received SPAs from FDA for a pair of similar, open-label, international Phase III trials of NAV5001 each in up to 275 patients. The trials are slated to begin later this year. One trial...
07:00 , Apr 8, 2013 |  BC Week In Review  |  Clinical News

Altropane: Clinical trial started

Navidea said investigators began an open-label, U.S. clinical trial to evaluate NAV5001 in healthy volunteers. This year, Navidea plans to start a Phase IIb trial NAV5001 in the indication. The imaging agent is also in...
07:00 , Aug 6, 2012 |  BC Week In Review  |  Company News

Alseres, Navidea deal

Navidea exercised its option under a January deal to license exclusive, worldwide rights to develop and commercialize imaging agent Altropane from Alseres. Alseres will receive $175,000 up front and 300,000 shares of Navidea stock. The...
07:00 , Jul 2, 2012 |  BC Week In Review  |  Company News

Alseres, Navidea deal

Navidea elected to extend to July 31 from June 30 its option to license exclusive, worldwide rights to imaging agent Altropane from Alseres. The decision triggers a $250,000 payment to Alseres. Under the terms of...
08:00 , Jan 30, 2012 |  BC Week In Review  |  Company News

Alseres, Navidea deal

Alseres granted Navidea an option to license exclusive, worldwide rights to imaging agent Altropane by June 30. Alseres received $500,000 for the option and could receive an additional $250,000 if Navidea extends the option to...
08:00 , Feb 9, 2009 |  BC Week In Review  |  Clinical News

Altropane: Completed Phase III enrollment

Alseres completed enrollment of 60 patients in the open-label first stage of the Phase III POET-2 program. The first stage was designed to acquire a set of Altropane images that will be used to train...